Reframing Major Depressive Disorder: Advancing Long-Term Management to Reduce Relapse and Recurrence

Major depressive disorder (MDD) is often recurrent, and achieving remission does not eliminate the risk of future episodes. Each recurrent episode can deepen the neurobiological, psychiatric, medical, economic, and quality-of-life burden while increasing the risk of future episodes. Yet, relapse prevention is not consistently established as a distinct treatment goal, and systematic assessment and stratification of recurrence risk remains uneven in practice. Clinicians need practical strategies to look beyond acute symptom relief, recognize recurrence risk as modifiable, and manage MDD across the full disease trajectory. By bringing together expert insight, real-world patient cases, community perspectives, and the lived experiences of people with MDD, this activity will reveal opportunities to shift from episodic treatment toward proactive, long-term care.

This fast-paced and highly interactive live CaseWise™ webcast from CME Outfitters will challenge learners to examine clinical decisions through the perspectives of experts, peers, patients, and a validated artificial intelligence (AI) clinical-reasoning platform. Through dynamic patient cases, learners will explore the cumulative burden of recurrent MDD, apply a relapse-prevention framework, integrate evidence-based recurrence risk assessment into routine care, and engage patients in shared relapse-prevention planning.

At the conclusion of this activity, learners will be able to better:

• Evaluate the cumulative, multidomain burden (neurobiological, psychiatric, medical, economic, and quality-of-life) that accrues across recurrent major depressive episodes
• Apply a relapse-prevention framework that treats recurrence risk as modifiable and establishes relapse prevention as an explicit, distinct treatment goal, using consistent definitions of relapse and recurrence
• Integrate systematic, evidence-based assessment and stratification of relapse/recurrence risk into routine clinical encounters

This activity is supported through an independent educational grant from Lilly.

Psychiatrists, psychiatric physician associates (PAs) and nurse practitioners (NPs), psychiatric nurses, behavioral health HCPs (psychologists, therapists, social workers, and case managers), and psychiatric clinical pharmacists

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Clayton reports the following financial relationships:

Advisory Board: AbbVie Inc.; Accumin Inc.; Actinogen Medical Limited; AdhereTech, Inc.; Axsome Therapeutics, Inc.; Aytu BioPharma, Inc.; Biogen Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Intra-Cellular Therapies, Inc.; Janssen Research & Development, LLC; LivaNova PLC; Neumora Therapeutics, Inc.; Sirtsei Pharmaceuticals, Inc.; and Vella Bioscience, Inc.

Consultant: Autobahn Therapeutics, Inc.; Axsome Therapeutics, Inc.; Aytu BioPharma, IncIntra-Cellular Therapies, Inc.; Janssen Research & Development, LLC; Lilly (DSMB x2); Mentavi, Inc.; MycoMedica Life Sciences; Neurocrine Biosciences, Inc.; Reunion Neuroscience Inc.; S1 Biopharma, Inc.; and Seaport Therapeutics, Inc.

Grants: Dare Bioscience, Inc.; Janssen Research & Development, LLC; National Institutes of Health (NIH); Neumora Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka Pharmaceutical Co., Ltd.; Relmada Therapeutics, Inc.; Reunion Neuroscience Inc.; and S1 Biopharma, Inc.

Stock Shareholder (ownership interest): Mediflix LLC and S1 Biopharma, Inc. (Shares/Restricted Stock Units)

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
Kashemi D. Rorie, PhD (Planning Committee)
Lexie Oneca (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

WC-165-111826-11